
News|Articles|December 3, 2025
Unlocking Speed and Scalability in Biologics: GPEx® Lightning Executive Overview
Author(s)Catalent
Discover how Catalent’s GPEx® Lightning platform revolutionizes cell line development for complex biologics. This executive summary highlights how the platform enables rapid, high-titer expression of multispecific antibodies and other challenging proteins—accelerating timelines, improving production efficiency, and supporting commercial-scale manufacturing. Learn how tunable expression and digital control empower your team to overcome development bottlenecks and drive innovation in next-generation biologics.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
FDA Launches PreCheck Pilot Program to Bolster Domestic Drug Manufacturing
2
Cellares Scales IDMO Model for Gene-Edited Stem Cells Therapies
3
Women in STEM: Cultivating Scientific Confidence
4
Bristol Myers Squibb and Johnson & Johnson Launch Educational Program for Thromboembolic R&D
5